A61P 13 - Drugs for disorders of the urinary system

Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
12/2002
12/12/2002	US20020187968 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-DIOL
12/12/2002	US20020187967 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002	US20020187966 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002	US20020187965 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002	US20020187964 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002	US20020187963 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002	US20020187962 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002	US20020187472 Nucleotide sequences coding protein for use in the treatment of cancer
12/12/2002	US20020187134 Prebiotic and probiotic compositions and methods for their use in gut-based therapies
12/12/2002	DE10125883A1 Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie Medicines containing an effector of the glutathione metabolism together with alpha-lipoic acid in the context of renal replacement therapy
12/12/2002	CA2449771A1 Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins
12/12/2002	CA2449175A1 Use of methylnaltrexone to treat immune suppression
12/12/2002	CA2449109A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/12/2002	CA2449097A1 5-ethyl-imidazotriazinones
12/12/2002	CA2449021A1 Novel compounds and compositions as cathepsin inhibitors
12/12/2002	CA2448606A1 Nucleic acid-associated proteins
12/12/2002	CA2448427A1 Molecules and methods for inhibiting shedding of kim-1
12/12/2002	CA2448418A1 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
12/12/2002	CA2447732A1 Antineoplastic combinations
12/12/2002	CA2447695A1 Modified antibodies to prostate-specific membrane antigen and uses thereof
12/12/2002	CA2445460A1 Carboline derivatives as pde-5 inhibitors
12/12/2002	CA2436408A1 Modified psma ligands and uses related thereto
12/11/2002	WO2001083471A1 Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof
12/11/2002	EP1264829A1 Oxygen-containing heterocyclic compounds
12/11/2002	EP1263959A1 Antibodies to human cd154
12/11/2002	EP1263786A2 Methods and compositions for immunoregulation
12/11/2002	EP1263780A2 Liv-1 related protein, polynulceotides encoding the same and use thereof for treatment of cancer
12/11/2002	EP1263767A2 Beta netrin and uses thereof
12/11/2002	EP1263761A2 Compounds for pdt
12/11/2002	EP1263760A1 Novel compounds
12/11/2002	EP1263757A1 Benzthiazoles as tnf and pde-iv inhibitors
12/11/2002	EP1263736A1 2-carboxamide-benzimidazoles useful in the treatment and prevention of ischemic reperfusion injury
12/11/2002	EP1263732A1 Corticotropin releasing factor antagonists
12/11/2002	EP1263730A1 Amine derivatives for the treatment of apoptosis
12/11/2002	EP1263725A1 Novel compounds
12/11/2002	EP1263724A1 Novel compounds
12/11/2002	EP1263464A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function
12/11/2002	EP1149104B1 Pyrrolobenzodiazepine carboxyamide vasopressin agonists
12/11/2002	EP1148791B1 Protein material for slow digestion and its use
12/11/2002	EP1071433B1 2',2'-difluoronucleosides for immunosuppressive therapy and combined pharmaceutical compositions
12/11/2002	EP0793498B1 Bicyclic heterocyclic compounds for the treatment of impotence
12/11/2002	EP0750909B1 The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
12/11/2002	EP0723447B1 Use of (2-imidazolin-2-ylamino) quinoxaline derivatives
12/11/2002	CN1384830A Novel spiroheterocyclic compoundsus reversible inhibitors of cysteine proteases
12/11/2002	CN1384829A Sodium-hydrogen exchanger type 1 inhibitor crystals
12/11/2002	CN1384822A Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-3,3-diphenylpropionate and use thereof endothelin antagonist
12/11/2002	CN1384754A Method and composition for treating prostate cancer
12/11/2002	CN1384752A Remedies for nervous diseases
12/11/2002	CN1384740A Delayed-action form of administration containing tramadol saccharinate
12/11/2002	CN1384739A Oral pharmaceutical forms of administration with a delayed action
12/11/2002	CN1384735A Oral dosage forms
12/11/2002	CN1384100A Benzo-1,3-dioxole and benzofuran substituted pentazane derivative
12/11/2002	CN1383886A Prostatosis treating pill made of 18 kinds of Chinese medicine material
12/11/2002	CN1383875A Suppository for treating prostatosis and its production process
12/11/2002	CN1383868A Fleeceflower root tea
12/11/2002	CN1383859A Health tea
12/11/2002	CN1383857A Medicine for treating incomplete kidney function and its prepn
12/11/2002	CN1095668C Use of combination of progestational agent and nitric oxide synthetase substrate and/or donor in prep. of medicine for treatment of preeclampsia and preterm labor
12/11/2002	CA2411165A1 Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof
12/10/2002	US6492497 Specific binding members for TGFbeta1
12/10/2002	US6492422 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
12/10/2002	US6492412 Prevention of loss and restoration of bone mass by certain prostaglandin agonists
12/10/2002	US6492406 Pharmaceutically active compounds
12/10/2002	US6492403 Methods of treating C1s-mediated diseases and conditions and compositions thereof
12/10/2002	US6492401 Sodium hydrogen exchanger type 1 inhibitors; reducing perioperative myocardial tissue damage
12/10/2002	US6492393 Compounds useful as anti-inflammatory agents
12/10/2002	US6492372 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
12/10/2002	US6492367 Sulfamato hydroxamic acid metalloprotease inhibitor
12/10/2002	US6492325 Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
12/10/2002	US6492129 Fragments comprising the n-terminal region of connective tissue growth factor (ctgf); screening for inhibitors or stimulators of ctgf
12/10/2002	CA2208792C Substituted indazole derivatives
12/08/2002	CA2817619A1 Methods of administering anti-tnf.alpha. antibodies
12/08/2002	CA2385745A1 Methods of administering anti-tnf.alpha. antibodies
12/05/2002	WO2002097087A1 Method of expressing foreign gene in kidney
12/05/2002	WO2002097060A2 Carbohydrate-associated proteins
12/05/2002	WO2002097030A2 Peptides derived from neural thread proteins and their medical use
12/05/2002	WO2002096932A1 Transporters and ion channels
12/05/2002	WO2002096888A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
12/05/2002	WO2002096887A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
12/05/2002	WO2002096883A1 Tricyclic compounds useful as angiotensin ii agonists
12/05/2002	WO2002096879A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
12/05/2002	WO2002096876A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	WO2002096867A2 Inhibitors of protein kinase for the treatment of disease
12/05/2002	WO2002096866A2 Thiolalkyl benzoic acid derivatives
12/05/2002	WO2002096864A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	WO2002096855A2 Anticholinergic compounds and methods of use
12/05/2002	WO2002096468A2 Method for the diagnosis and therapy of renal cell carcinoma
12/05/2002	WO2002096457A2 Stable liquid formulations of antibodies
12/05/2002	WO2002096453A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
12/05/2002	WO2002096419A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	WO2002096414A1 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy
12/05/2002	WO2002096408A1 Coenzyme q and eicosapentaenoic acid (epa)
12/05/2002	WO2002096363A2 Method for treating fibrotic diseases or other indications
12/05/2002	WO2002096362A2 Method for treating fibrotic diseases or other indications vi
12/05/2002	WO2002096360A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	WO2002096358A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002080854A3 Compositions and methods for the prevention and treatment of human prostate cancer
12/05/2002	WO2002078633A8 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002066450A3 Anthrone derivatives and their use as ink inhibitors

1 ... 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 ... 562